Clinical Trial Update: Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating letrozole with metronomic capecitabine in ER-positive, HER2-negative advanced/metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Letrozole (letrozole)

Snippet

Sponsor: Cairo University | Conditions: Breast Cancer, Estrogen Receptor-positive Breast Cancer | Phase 2 | Status: UNKNOWN